UA110347C2 - ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A - Google Patents

ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A

Info

Publication number
UA110347C2
UA110347C2 UAA201302834A UAA201302834A UA110347C2 UA 110347 C2 UA110347 C2 UA 110347C2 UA A201302834 A UAA201302834 A UA A201302834A UA A201302834 A UAA201302834 A UA A201302834A UA 110347 C2 UA110347 C2 UA 110347C2
Authority
UA
Ukraine
Prior art keywords
medicaments
diseases
manufacture
dyhidropirazol
pde9a
Prior art date
Application number
UAA201302834A
Other languages
English (en)
Russian (ru)
Inventor
Ніклас Хайне
Крістіан Айкмайєр
Марко Феррара
Ріккардо Джованніні
Хольгер Розенброк
Герхард Шенцле
Original Assignee
Бьорінгер Інгельхайм Інтернаціональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бьорінгер Інгельхайм Інтернаціональ Гмбх filed Critical Бьорінгер Інгельхайм Інтернаціональ Гмбх
Publication of UA110347C2 publication Critical patent/UA110347C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Даний винахід стосується нових 6-циклоалкілпіразолопіримідинонів формули (І), де R1 означає 5- або 6-членну ароматичну гетероарильну групу, R2 означає необов'язковий замісник, D означає необов'язково заміщений циклопентил, циклогексил, тетрагідрофураніл, тетрагідропіраніл або 2-, 3- або 4-піридил, m=1 або 2 і n дорівнює 0, 1 або 2. Ці нові сполуки придатні для застосування як активного компонента лікарських засобів або для приготування лікарських засобів, відповідно, зокрема лікарських засобів, призначених для лікування патологічних станів, пов'язаних з недостатністю сприйняття, зосередженості, здатності до навчання або пам'яті. Такі патологічні стани можуть бути пов'язані, наприклад, з хворобою Альцгеймера, шизофренією і іншими захворюваннями. Ці нові сполуки також застосовні, наприклад, для приготування лікарських засобів і/або для застосування для лікування цих захворювань, зокрема порушення пізнавальної здатності, пов'язаного з таким захворюванням. Сполуки, пропоновані в даному винаході, є інгібіторами PDE9. EMBED ISISServer (I)
UAA201302834A 2010-08-12 2011-08-09 ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A UA110347C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10172597 2010-08-12
EP11154397 2011-02-14
PCT/EP2011/063705 WO2012020022A1 (en) 2010-08-12 2011-08-09 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors

Publications (1)

Publication Number Publication Date
UA110347C2 true UA110347C2 (uk) 2015-12-25

Family

ID=45567392

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201302834A UA110347C2 (uk) 2010-08-12 2011-08-09 ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A

Country Status (30)

Country Link
US (2) US8912201B2 (uk)
EP (2) EP2603511B1 (uk)
JP (1) JP5756176B2 (uk)
KR (1) KR101918909B1 (uk)
CN (2) CN105541849B (uk)
AP (1) AP2012006631A0 (uk)
AR (1) AR082667A1 (uk)
AU (1) AU2011288503C1 (uk)
BR (1) BR112013003097B1 (uk)
CA (1) CA2807687C (uk)
CL (1) CL2013000368A1 (uk)
CO (1) CO6670591A2 (uk)
DK (1) DK2603511T3 (uk)
EA (1) EA024984B1 (uk)
ES (1) ES2626006T3 (uk)
GE (1) GEP20156217B (uk)
HK (1) HK1178539A1 (uk)
HU (1) HUE033378T2 (uk)
IL (1) IL223347A (uk)
MX (1) MX344770B (uk)
MY (1) MY170189A (uk)
NZ (1) NZ603725A (uk)
PE (1) PE20130602A1 (uk)
PL (1) PL2603511T3 (uk)
SG (1) SG187081A1 (uk)
TN (1) TN2013000051A1 (uk)
TW (1) TWI510490B (uk)
UA (1) UA110347C2 (uk)
UY (1) UY33556A (uk)
WO (1) WO2012020022A1 (uk)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
NZ590788A (en) 2008-09-08 2012-11-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of cns disorders
AP2011005819A0 (en) 2009-03-31 2011-08-31 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators.
EP2603511B1 (en) 2010-08-12 2017-03-15 Boehringer Ingelheim International GmbH 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
AU2013269800A1 (en) * 2012-05-30 2014-10-09 F. Hoffmann-La Roche Ag Triazolo compounds as PDE10 inhibitors
TWI653041B (zh) 2012-06-04 2019-03-11 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
PL400149A1 (pl) 2012-07-26 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne pirazolo[3,4-d]pirymidyno-4(5H)-onu jako inhibitory PDE9
CN102786525B (zh) 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
CA2908482A1 (en) * 2013-03-01 2014-09-04 Fundacion Para La Investigacion Medica Aplicada Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
MY203464A (en) 2014-01-21 2024-06-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
CN108218874B (zh) * 2016-12-21 2020-10-30 南京药捷安康生物科技有限公司 一种磷酸二酯酶抑制剂及其用途
JP7111720B2 (ja) * 2016-12-28 2022-08-02 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物
AU2018225373C1 (en) * 2017-02-23 2022-05-12 Boehringer Ingelheim International Gmbh New medical use of compound III
CN110603039B (zh) 2017-06-01 2023-02-28 卫材R&D管理有限公司 组合吡唑并喹啉衍生物和美金刚的痴呆治疗剂
CN116585316A (zh) 2017-06-01 2023-08-15 卫材R&D管理有限公司 包含pde9抑制剂的药物组合物
BR112019023552A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina
SG10202113198TA (en) 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
EP3634964B1 (en) * 2017-06-08 2022-02-23 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde9 inhibitors
CN111212839A (zh) * 2017-09-15 2020-05-29 艾杜罗生物科技公司 吡唑并嘧啶酮化合物及其用途
CN110627795A (zh) * 2018-06-21 2019-12-31 南京药捷安康生物科技有限公司 磷酸二酯酶抑制剂及其用途
CN108785677A (zh) * 2018-07-10 2018-11-13 仙鹤生物科技（杭州）有限公司 PDE9A抑制剂在制备提升Treg含量的制品、防治炎性肠病的药物及保健品中的应用
KR102706457B1 (ko) * 2018-12-06 2024-09-11 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
KR102712818B1 (ko) * 2018-12-06 2024-09-30 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
US20220017525A1 (en) 2018-12-12 2022-01-20 Merck Sharp & Dohme Corp. Cyclobutyl pyrazolopyrimidine pde9 inhibitors
CN114057698B (zh) * 2020-08-10 2023-08-15 暨南大学附属第一医院（广州华侨医院） Pde10a受体靶向型正电子药物[18f]p10a-1910的研制与应用

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3165520A (en) 1965-01-12 Certificate of correction
DE149013C (uk)
US3169965A (en) 1965-02-16 New x-mercapto-pyrazolo
DE147234C (uk) 1902-06-25
CH396926A (de) 1960-05-11 1965-08-15 Ciba Geigy Verfahren zur Herstellung neuer Pyrazolopyrimidine
ES267249A1 (es) 1960-05-11 1961-11-01 Ciba Geigy Procedimiento para la obtencion de pirazolo-pirimidinas nuevas
DE1156415B (de) 1960-05-11 1963-10-31 Ciba Geigy Verfahren zur Herstellung von 1-Isopropyl-4-hydroxy-pyrazolo [3, 4-d]-pyrimidinen
DE1161281B (de) 1960-05-11 1964-01-16 Ciba Aktiengesellschaft, Basel (Schweiz) Verfahren zur Herstellung von 1-Alkyl-6-aralkyl-pyrazoloÄ3,4-dÜ-pyrimidinen.
CH396925A (de) 1960-05-11 1965-08-15 Ciba Geigy Verfahren zur Herstellung neuer Pyrazolopyrimidine
GB937723A (en) 1960-05-11 1963-09-25 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
CH398626A (de) 1960-05-11 1966-03-15 Ciba Geigy Verfahren zur Herstellung neuer Pyrazolopyrimidine
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE1153023B (de) 1960-05-11 1963-08-22 Ciba Geigy Verfahren zur Herstellung von 4-Hydroxy-pyrazolo[3,4-d] pyrimidinen
DE1149013B (de) 1960-05-11 1963-05-22 Ciba Geigy Verfahren zur Herstellung von 4-Oxo-4, 5-dihydro-pyrazolo-[3, 4-d]Pyrimidinen
CH396927A (de) 1960-05-11 1965-08-15 Ciba Geigy Verfahren zur Herstellung neuer Pyrazolopyrimidine
CH396923A (de) 1960-05-11 1965-08-15 Ciba Geigy Verfahren zur Herstellung von 4-Mercapto-pyrazolo(3,4-d)pyrimidinen
DE1147234B (de) 1960-05-11 1963-04-18 Ciba Geigy Verfahren zur Herstellung von 1-Isopropyl-4-hydroxy-6-benzyl-pyrazolo[3, 4-d]pyrimidin
CH396924A (de) 1960-05-11 1965-08-15 Ciba Geigy Verfahren zur Herstellung von 4-Mercapto-pyrazolo(3,4-d)pyrimidinen
US3244328A (en) 1964-03-23 1966-04-05 Corning Glass Works Dispensing from plural sources
US3732225A (en) 1970-07-23 1973-05-08 Squibb & Sons Inc Pyrazolo(3,4-d)pyrimidine derivatives
NL167151C (nl) 1971-04-09 1981-11-16 Acf Chemiefarma Nv Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen.
US3847908A (en) 1973-03-05 1974-11-12 Squibb & Sons Inc 6-styrylpyrazolo(3,4-d)pyrimidinones and pyrimidines
GR82004B (uk) 1983-06-30 1984-12-12 American Home Prod
US4602023A (en) 1985-06-03 1986-07-22 Warner-Lambert Company Diphenic acid monoamides
DE3739366A1 (de) 1987-04-10 1988-10-27 Boehringer Mannheim Gmbh Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel
US6211158B1 (en) 1987-04-10 2001-04-03 Roche Diagnostics Gmbh Desazapurine-nucleotide derivatives, processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof for nucleic acid sequencing and as antiviral agents
US5684164A (en) 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5466806A (en) 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
HU226137B1 (en) 1989-02-08 2008-05-28 Shire Canada Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
JP2619710B2 (ja) 1989-02-27 1997-06-11 日本製紙 株式会社 ２′，３′−ジデオキシプリンヌクレオシド類の製造方法
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
US5113855A (en) 1990-02-14 1992-05-19 Newhouse Michael T Powder inhaler
US5002949A (en) 1990-05-01 1991-03-26 American Home Products Corporation 5-substituted-6-aminopyrimidine derivatives
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
CA2100863A1 (en) 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
FR2676929B1 (fr) 1991-05-30 1994-02-11 Aerosols Bouchage Ste Fse Inhalateur de poudres.
US5341801A (en) 1991-12-03 1994-08-30 Sandoz Ltd. Inhaler
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
FR2700279B1 (fr) 1993-01-14 1995-03-17 Valois Dispositif portatif pour projeter des doses d'une substance fluide à l'aide d'un flux d'air comprimé.
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US5256668A (en) 1993-03-17 1993-10-26 American Home Products Corporation Aminopyrimidine derivatives as antiviral agents for respiratory syncytial virus
JP3132830B2 (ja) 1993-05-12 2001-02-05 帝人株式会社 粉末状薬剤マルチドース施薬装置
EP0626387B1 (de) 1993-05-12 1999-03-10 Novartis AG Nukleoside und Oligonukleotide mit 2'-Ethergruppen
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
PT679657E (pt) 1994-04-27 2003-11-28 Novartis Ag Nucleosidos e oligonucleotidos com grupos 2'-eter
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6072051A (en) 1995-11-02 2000-06-06 Chong Kun Dang Corp. Nucleoside derivatives and process for preparing the same
ATE251638T1 (de) 1996-06-06 2003-10-15 Novartis Pharma Gmbh 2-substituierte nukleosid- und oligonukleotid- derivate
WO1998000434A1 (en) 1996-06-28 1998-01-08 Novartis Ag Modified oligonucleotides
JP2001500865A (ja) 1996-09-13 2001-01-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 避妊の非ホルモン法
IL129118A0 (en) 1996-10-16 2000-02-17 Icn Pharmaceuticals Purine L-nucleosides analogs and uses thereof
US6509320B1 (en) 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US5948812A (en) 1997-06-09 1999-09-07 Givaudan Roure (International) Sa 1,7-dioxacycloalkan-8-one compounds
US5969499A (en) 1997-09-10 1999-10-19 Shaffer; Randall A Controller for AC motor
JP2002503662A (ja) 1998-02-17 2002-02-05 テュラリク インコーポレイテッド 抗ウイルス性ピリミジン誘導体
DE19838705A1 (de) 1998-08-26 2000-03-02 Bayer Ag Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
CA2348979A1 (en) 1998-11-02 2000-05-11 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions
US6225315B1 (en) 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
US6100037A (en) 1999-01-07 2000-08-08 Incyte Pharmaceuticals, Inc. Human cyclic nucleotide PDEs
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
NZ521210A (en) 2000-02-18 2004-11-26 Shire Biochem Inc Method for the treatment or prevention of flavivirus infections using nucleoside analogues
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6369222B1 (en) 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
EP1307201B1 (de) 2000-08-01 2004-11-24 Bayer HealthCare AG Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
AU2001277621A1 (en) 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
CA2415871A1 (en) 2000-08-24 2002-02-28 Novartis Ag Process for surface modifying substrates and modified substrates resulting therefrom
US6581338B2 (en) 2000-10-20 2003-06-24 Myron N. Koenig Escapable area well cover
US20020074774A1 (en) 2000-12-14 2002-06-20 Davin Hsu Adjustable handle of umbrella stroller by telescoping and swiveling
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
US6777395B2 (en) 2001-01-22 2004-08-17 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase of hepatitis C virus
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
GB0106661D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
HUP0600232A2 (en) 2001-04-11 2006-08-28 Bristol Myers Squibb Co Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
US20040185459A1 (en) 2001-04-18 2004-09-23 Masami Otsuka Hybridization probe
JP4049742B2 (ja) 2001-06-01 2008-02-20 エフ．ホフマン−ラ ロシュ アーゲー グルタミン酸受容体としてのピリミジン、トリアジン及びピラジン誘導体
US7067507B2 (en) 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
WO2003011925A1 (en) 2001-07-25 2003-02-13 Ppg Industries Ohio, Inc. High refractive index optical resin composition
EP1283226A1 (en) 2001-07-31 2003-02-12 Resolution Research Nederland B.V. Hydroxyl-functional copolymer and coating compositions formed therewith
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
WO2003031458A1 (en) 2001-10-12 2003-04-17 Dana-Farber Cancer Institute Methods for synthesis of diarylmethanes
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
EP1444009A1 (en) 2001-11-02 2004-08-11 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
DE10156249A1 (de) 2001-11-15 2003-05-28 Bayer Ag Regulation der cGMP-spezifischen Phosphodiesterase 9A
WO2003072757A2 (en) 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
WO2003099840A1 (en) 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
CN104163841B (zh) 2002-06-28 2016-08-24 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
AU2003252003A1 (en) 2002-07-19 2004-02-09 David B. Mossor Portable shielding system
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238725A1 (de) 2002-08-23 2004-03-04 Bayer Cropscience Ag Substituierte Heterocyclypyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10244795A1 (de) 2002-09-26 2004-04-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
MXPA05005192A (es) 2002-11-15 2005-09-08 Idenix Cayman Ltd Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae.
EP1581543A4 (en) 2003-01-03 2008-03-19 Bristol Myers Squibb Co METHODS FOR PRODUCING SGLT2 GLYCOSIS C-ARYL INHIBITORS
EP1460077B1 (en) 2003-03-18 2007-08-01 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Novel pyrazolopyrimidones and their use as PDE inhibitors
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
JP2006525966A (ja) 2003-05-09 2006-11-16 バイエル・ヘルスケア・アクチェンゲゼルシャフト ６−シクリルメチル−および６−アルキルメチル置換ピラゾロピリミジン類
US8044060B2 (en) * 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
SI1631295T1 (sl) 2003-06-06 2010-06-30 Arexis Ab Uporaba kondenziranih heterocikličnih spojin kotSCCE inhibitorjev za zdravljenje kožnih bolezni
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
DE502004008951D1 (de) 2003-08-26 2009-03-19 Boehringer Ingelheim Pharma Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
EP1664061B1 (en) * 2003-09-22 2017-03-15 GlaxoSmithKline Australia Pty Ltd Process for the synthesis of morphinane compounds and intermediates thereof
EP1685127A1 (en) 2003-11-21 2006-08-02 The University of Connecticut Heterocyclyl-substituted oxetanes for the treatment of proliferative or infectious diseases
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
DE102004012093A1 (de) 2004-03-05 2005-09-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator mit Merkanaldüse
CN103030617A (zh) 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1773800A1 (de) 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
ATE407938T1 (de) 2004-12-16 2008-09-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
DOP2006000009A (es) 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
US7951810B2 (en) 2005-02-04 2011-05-31 Millennium Pharmaceuticals, Inc. Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes
DE602006009772D1 (de) 2005-02-23 2009-11-26 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
ES2338041T3 (es) 2005-04-15 2010-05-03 Boehringer Ingelheim International Gmbh Derivados de (heteroariloxi-bencil)-benceno sustituidos con glucopiranosilo en calidad de inhibidores de sglt.
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005024493A1 (de) 2005-05-27 2006-11-30 Bayer Healthcare Ag Verwendung von Pyrazolopyrimidinen
JP5128474B2 (ja) 2005-07-27 2013-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換（（ヘテロ）シクロアルキルエチニル−ベンジル）−ベンゼン誘導体、該化合物を含有する薬剤、それらの使用及びそれらの製造方法
AR056191A1 (es) 2005-08-23 2007-09-26 Idenix Phatmaceuticals Inc Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae
EP1924571B1 (en) 2005-08-30 2010-10-13 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
US7488766B2 (en) 2005-10-06 2009-02-10 Sabic Innovative Plastics Ip B.V. Polymer composition, method, and article
TW200815361A (en) 2005-10-20 2008-04-01 Astrazeneca Ab Chemical compounds
JP2009531291A (ja) 2006-02-15 2009-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
EP1844805A1 (de) 2006-04-13 2007-10-17 Boehringer Ingelheim Pharma GmbH & Co.KG Inhalator
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
EP2054426A1 (en) 2006-08-15 2009-05-06 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
DE102006044752A1 (de) 2006-09-20 2008-04-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kolbendosierer
JP5372759B2 (ja) 2006-09-21 2013-12-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換ジフルオロベンジル−ベンゼン誘導体、該化合物を含有する医薬品及びその使用と調製方法
JP2010507629A (ja) 2006-10-27 2010-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−（β−Ｄ−グルコピラノス−１−イル）−１−メチル−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）−ベンジル］−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用
TW200829258A (en) 2006-11-06 2008-07-16 Boehringer Ingelheim Int Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008055959A1 (en) 2006-11-09 2008-05-15 Galapagos N.V. Novel compounds useful for the treatment of degenerative & inflammatory diseases
CA3007700A1 (en) 2006-11-09 2008-05-15 Boehringer Ingelheim International Gmbh Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
EP2099456A2 (en) * 2006-11-22 2009-09-16 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
EP2124965A1 (en) 2007-01-26 2009-12-02 Boehringer Ingelheim International GmbH Methods for preventing and treating neurodegenerative disorders
JP2008183929A (ja) 2007-01-26 2008-08-14 Toshiba Corp Ｖｏｒモニタ受信装置及びｖｏｒモニタ受信方法
WO2008100447A2 (en) 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
EP2125768A1 (en) 2007-02-21 2009-12-02 Boehringer Ingelheim International GmbH Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
SI2152712T1 (sl) 2007-05-11 2012-03-30 Pfizer Amino heterociklične spojine
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
JP2011512209A (ja) 2008-02-20 2011-04-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 粉末吸入器
US20090235929A1 (en) 2008-03-19 2009-09-24 Marc Egen Powder inhalers
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
NZ590788A (en) 2008-09-08 2012-11-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of cns disorders
AU2010212865A1 (en) 2009-02-13 2011-07-21 Boehringer Ingelheim International Gmbh SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
SI2395983T1 (sl) 2009-02-13 2020-08-31 Boehringer Ingelheim International Gmbh Farmacevtski sestavek, ki obsega SGLT2 inhibitor, DPP-IV inhibitor in po izbiri nadaljnje antidiabetično sredstvo in uporabe le-teh
CN105147662A (zh) 2009-02-13 2015-12-16 贝林格尔·英格海姆国际有限公司 包含吡喃葡萄糖基二苯基甲烷衍生物的药物组合物及其药物剂型、制备方法与用途
AP2011005819A0 (en) 2009-03-31 2011-08-31 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators.
TW201118099A (en) * 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
ES2546762T3 (es) 2009-09-30 2015-09-28 Boehringer Ingelheim International Gmbh Procedimientos para preparar derivados de bencil-benceno sustituidos con glucopiranosilo
JP5736377B2 (ja) 2009-09-30 2015-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １−クロロ−４−（β−Ｄ−グルコピラノス−１−イル）−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）ベンジル］ベンゼンの結晶形の調製方法
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
EP2603511B1 (en) 2010-08-12 2017-03-15 Boehringer Ingelheim International GmbH 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors

Also Published As

Publication number Publication date
UY33556A (es) 2012-03-30
TWI510490B (zh) 2015-12-01
EP2603511A1 (en) 2013-06-19
CA2807687A1 (en) 2012-02-16
AU2011288503C1 (en) 2015-08-06
AU2011288503B2 (en) 2015-02-12
IL223347A (en) 2017-10-31
US20150025088A1 (en) 2015-01-22
AR082667A1 (es) 2012-12-26
AP2012006631A0 (en) 2012-12-31
AU2011288503A1 (en) 2012-12-13
GEP20156217B (en) 2015-01-12
CN105541849A (zh) 2016-05-04
HUE033378T2 (en) 2017-11-28
DK2603511T3 (en) 2017-05-08
PE20130602A1 (es) 2013-05-25
US20120202829A1 (en) 2012-08-09
EP3053924A1 (en) 2016-08-10
US9328120B2 (en) 2016-05-03
KR101918909B1 (ko) 2018-11-15
JP2013533302A (ja) 2013-08-22
CN103052639A (zh) 2013-04-17
WO2012020022A1 (en) 2012-02-16
CN105541849B (zh) 2018-03-23
CN103052639B (zh) 2016-02-17
EA024984B1 (ru) 2016-11-30
SG187081A1 (en) 2013-03-28
MY170189A (en) 2019-07-09
KR20130139834A (ko) 2013-12-23
MX344770B (es) 2017-01-06
JP5756176B2 (ja) 2015-07-29
BR112013003097B1 (pt) 2021-03-16
ES2626006T3 (es) 2017-07-21
PL2603511T3 (pl) 2017-08-31
CA2807687C (en) 2019-01-08
US8912201B2 (en) 2014-12-16
HK1178539A1 (zh) 2013-09-13
BR112013003097A2 (pt) 2016-06-28
NZ603725A (en) 2015-04-24
AU2011288503A8 (en) 2013-01-10
CL2013000368A1 (es) 2013-06-07
TW201305168A (zh) 2013-02-01
EA201201664A1 (ru) 2013-07-30
MX2013001335A (es) 2013-03-22
TN2013000051A1 (en) 2014-06-25
EP2603511B1 (en) 2017-03-15
CO6670591A2 (es) 2013-05-15

Similar Documents

Publication Publication Date Title
UA110347C2 (uk) ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
TN2013000324A1 (en) 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitors
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
PH12016500531A1 (en) Compound inhibiting activities of btk and/or jak3 kinases
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MX2014010589A (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX2012004525A (es) Compuestos.
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MA33939B1 (fr) 5-alcynyl-pyrimidines
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
BR112013032720A2 (pt) "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
BR112015024678A2 (pt) inibidor da cinase
UA109459C2 (xx) ПОХІДНІ 5,6-ДИГІДРОІМІДАЗО[1,2-a]ПІРАЗИН-8-ІЛАМІНУ, ПРИДАТНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE)
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
MY155230A (en) Sulfoximine-substituted aniline pyrimidine derivatives as cdk inhibitors, their manufacture and use as medicine
PH12016500092A1 (en) New azabenzimidazole derivatives
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.